Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The platform will provide a safe and nurturing space for women, and non-binary individuals
The company plans to expand its portfolio in regulated markets aggressively
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
FUJIFILM will distribute iSWAB bio sampling technologies in Japan
More than 90,000 patients utilise the services daily
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Subscribe To Our Newsletter & Stay Updated
